UCSF scientist Joe Derisi named MaCarthur Fellow

September 28, 2004

Joseph DeRisi, PhD, of UCSF, has been named a 2004 MacArthur Fellow, one of the highest honors bestowed on an individual in the United States.

A molecular biologist, DeRisi has designed new tools for exploring the activity of genes, and used them to make major advances in understanding such infectious diseases as SARS (severe acute respiratory syndrome) and malaria. He is an associate professor of biochemistry and biophysics and Gordon M. Tomkins Chair at UCSF.

The honor, which includes $500,000 in support over the next five years, to be used at the recipient's discretion, is intended to "celebrate the creative individual in our midst," says Jonathan F. Fanton, president of the John D. and Catherine T. MacArthur Foundation, which bestows the honor. It is given in recognition of an individual's "originality, creativity and the potential to do more in the future."

It is the Foundation's conviction, says Fanton, "that talented individuals, free to follow their insights and instincts, will make a difference in shaping the future."

DeRisi, the only molecular biologist to be named in 2004, is one of 23 new fellows, who include such talents as a ragtime pianist, a novelist and an archaeological illustrator. The award is popularly referred to as the "genius award."

"I'm very surprised and extremely honored," says DeRisi, who learned about the award with a single phone call from the MacArthur Foundation last Tuesday, Sept. 21. "I feel like I'm in pretty extraordinary company."

Candidates are nominated for the award, evaluated and selected through a rigorous and confidential process, according to the Foundation. No one can apply for the awards, and no interviews are conducted.

"I have not before experienced anything coming close to the degree of transformation that Joe has brought about in our community," says Peter Walter, PhD, chairman and professor of the UCSF Department of Biochemistry and Biophysics. "He projects seemingly endless energy and infectious enthusiasm that, when combined with his outstanding science and generous, collaborative attitude, translates into new and wonderful things happening not just in his lab but in the whole community."

"If the McArthur Award is for geniuses, then they have found the right person," says UCSF Chancellor J. Michael Bishop.

Also named a 2004 MacArthur Fellow was Julie Theriot, PhD, formerly a UCSF Program in Biological Sciences (PIBS) graduate student in the laboratory of former UCSF scientist Tim Mitchison. Theriot, a microbiologist, cell biologist, and biophysicist, is focused on unraveling the secrets of bacterial infection.

In 1997, Eva Harris, PhD, formerly of the UCSF laboratory of Nina Agabian, PhD, in the UCSF Department of Stomatology, was named a MacArthur Fellow for her work in developing techniques to diagnose and treat disease in Central and South America.

DeRisi is the second member of the UCSF Department of Biochemistry and Biophysics to be named a MacArthur fellow. In 1987, the late Ira Herskowitz, PhD, a UCSF geneticist, received the honor. His studies on the yeast Saccharomyces cerevisiae yielded major insights into the fundamental aspects of cells. He was also a pioneer in pharmacogenetics -- the study of the way natural variations in individuals' genes affect their response to drugs.

DeRisi, who designs and builds microarrays -- a technology in which gene activity is revealed on a glass slide -- to carry out his studies on infectious diseases, says he plans to use the MacArthur funding to "drill deeper into malaria."

"I want to try new research directions in the field that would probably be too risky to be supported with traditional funding mechanisms," he says. "I want to learn more about the life cycle and internal regulatory mechanisms of the parasite, and how it avoids the immune system of the organisms it invades, with an eye toward drug development."

DeRisi, a faculty affiliate with the California Institute for Quantitative Biomedical Research (QB3), headquartered at UCSF's Mission Bay Campus, has already made significant strides against the malaria parasite, Plasmodium falciparum, which infects 200 to 300 million people world wide each year, mostly in tropical climates, such as sub Saharan Africa, and kills 700,000 to 2.7 million people annually, mostly children under the age of four.

In August 2003, he and his team reported that they had identified the full breadth of genetic activity at a key stage of development in the parasite, revealing that an unusually high percentage of genes ? at least 60 percent -- were "turned on," or expressed, at the third and critical stage in the parasite' s life cycle ? when it invades red blood cells and wreaks the havoc that causes the disease's symptoms.

Their analysis showed that the pattern, or timing, of gene expression was unique, with most genes expressed only once during the stage, and in a certain order, for a simple, continuous cascade of gene expression, beginning with genes that correspond to normal cellular processes and ending with highly specialized functions for invading red blood cells.

The discovery of the pronounced level of activity, in which a gene is transcribed into messenger RNA on the path toward producing a protein, points to numerous new potential targets for drug and vaccine therapy.

DeRisi is acutely aware of the need for such therapies, noting that Third World diseases such as malaria have not been a prime focus of pharmaceutical companies. "If you have an infectious disease like malaria, you're out of luck if don't have a credit card," he once said.

An outspoken advocate of making scientific findings freely accessible to scientists around the world, many of whom cannot afford to subscribe to scientific journals, DeRisi published his malaria finding in the new on-line, freely accessible science journal Public Library of Science Biology.

"Malaria is the number one killer in the Third World. But many scientists in countries like Brazil and India, who are carrying out very good science on malaria, don't have first world budgets," he said at the time.

DeRisi also focuses much of his energy on using his custom-built microarrays to move in on viruses that cause a variety of infectious diseases. In January 2003, he and his then-postdoctoral fellow David Wang used a microarray designed to detect all known viruses -- and even those never seen before -- to provide the confirming evidence that SARS was a novel form of a coronavirus. At the time, the head of the Centers for Disease Control and Prevention, Julie Gerberding, called his tool the "absolute state-of-the-art probe for viral genes."

But the self-described "viral hunter" is also applying the microarray to studies of diseases that, while less sensational in their debut, wreak havoc on people's lives. In collaboration with infectious disease specialist Don Ganem, MD, and pulmonologist Homer Boushey, MD, he is studying the viruses that may cause or exacerbate respiratory illnesses, including asthma. (Currently, scientists are only able to determine the specific viruses causing respiratory disease in 20 percent of cases.) He also is hoping to begin using the tool with neurologist Stephen Hauser, MD, to examine multiple sclerosis, which is believed to have a viral component in some cases.

Funding for developing this microarray and carrying out the ongoing respiratory studies is sponsored by an award from the Sandler Program for Asthma Research.

While microarray technology draws on the latest in computer chip technology, computation and bioinformatics, the essence of the tool is a simple 3 x 1 inch glass slide -- the kind found in a high school science laboratory. Scientists bond DNA or RNA sequences to the slide, wash fluorescently tagged DNA or RNA sequences of interest over it and see where the two sets of nucleic acid match up, as indicated by the fluorescent light. The outcome reveals which, if any of the genes in the sample of interest are active.

Ever interested in providing free access to scientific information, DeRisi has made a point of posting instructions on his website for making microarrays, and has given several workshops on their construction at Cold Spring Harbor and UC Santa Cruz.

"Joe has made a monumental effort to improve technology, creatively applying it to exciting disease-oriented problems, and making it accessible and freely available. Already, dozens of laboratories and hundreds of students have directly benefited from the resources he has developed and made available to the scientific community," says Walter.

"He is an outstanding researcher, a talented and dedicated teacher, an active participant in university and public service, and a wonderful human being. Joe's impact to date has been well beyond our wildest expectation. Among the many lucrative projects that could be tackled with microarray technology, Joe has focused a significant fraction of his research on malaria, a disease primarily afflicting the Third World. This focus is motivated by his genuine desire to have a positive impact on the human condition."
-end-


University of California - San Francisco

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.